UBS O'Connor’s Keros Therapeutics KROS Stock Holding History

UBS O'Connor’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37,891	Closed	-$506K	–	380
2025 Q2	$506K	Sell	37,891 -77,627	-67%	-$1.05M	0.01%	271
2025 Q1	$1.18M	Buy	115,518 +64,621	+127%	+$750K	0.03%	171
2024 Q4	$806K	Buy	50,897 +26,145	+106%	+$1.36M	0.02%	249
2024 Q3	$1.44M	Buy	24,752 +2,299	+10%	+$114K	0.04%	230
2024 Q2	$1.03M	Buy	22,453 +5,400	+32%	+$290K	0.03%	291
2024 Q1	$1.13M	Buy	17,053 +2,941	+21%	+$174K	0.03%	262
2023 Q4	$561K	Sell	14,112 -46,229	-77%	-$1.45M	0.02%	338
2023 Q3	$1.92M	Buy	60,341 +5,000	+9%	+$187K	0.03%	250
2023 Q2	$2.22M	Buy	55,341 +9,857	+22%	+$432K	0.05%	275
2023 Q1	$1.94M	Buy	+45,484	New	+$2.3M	0.05%	320
2022 Q4	–	Sell	-33,321	Closed	-$1.25M	–	176
2022 Q3	$1.25M	Sell	33,321 -24,000	-42%	-$832K	0.01%	719
2022 Q2	$1.58M	Buy	+57,321	New	+$2.52M	0.02%	699

Other funds holding KROS

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return